A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the <scp>FPR1</scp>/<scp>NLRP3</scp> Signaling Axis
Our findings suggest that LIGc holds promise in improving ischemic brain injury and neuroinflammation through modulation of microglia/macrophage polarization. Mechanistically, LIGc attenuates the pro-inflammatory phenotype and promotes the anti-inflammatory phenotype by targeting the FPR1/NLRP3 signaling pathway, ultimately reducing inflammatory responses and mitigating neurological damage.
Authors
- Jifei Liu (ORCID: https://orcid.org/0000-0002-7460-1939)
- Miao Chai
- Juan Gao (ORCID: https://orcid.org/0000-0001-6608-0312)
- Zhenchang Zhang (ORCID: https://orcid.org/0000-0002-1246-3745)
- Wei Chen (ORCID: https://orcid.org/0000-0001-8337-0880)
- Xiaodong Xie (ORCID: https://orcid.org/0000-0002-4895-0924)
- Manxia Wang (ORCID: https://orcid.org/0009-0008-5029-8518)
- Gang Su
- Jinyang Song
Institutions
- Chinese Academy of Sciences (CN)
- Lanzhou Institute of Chemical Physics (CN)
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/cns.70158
- Citations
- 6
- Primary Topic
- Neuroinflammation and Neurodegeneration Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.48
Funders
- National Natural Science Foundation of China